NCT04692051 - A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

March 1, 2021

Study Completion Date

September 1, 2021

Conditions

Biliary Tract Cancer

Interventions

DRUG

Nab-paclitaxel + Cisplatin

Nab-paclitaxel 125mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.

DRUG

Gemcitabine + Cisplatin

Gemcitabine1000mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.

Trial Locations (1)

RECRUITING

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan